WO2001025210A3 - Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosin-rezeptorliganden - Google Patents

Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosin-rezeptorliganden Download PDF

Info

Publication number
WO2001025210A3
WO2001025210A3 PCT/EP2000/009153 EP0009153W WO0125210A3 WO 2001025210 A3 WO2001025210 A3 WO 2001025210A3 EP 0009153 W EP0009153 W EP 0009153W WO 0125210 A3 WO0125210 A3 WO 0125210A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
receptor ligands
adenosine
aminopyridines
dicyano
Prior art date
Application number
PCT/EP2000/009153
Other languages
English (en)
French (fr)
Other versions
WO2001025210A2 (de
Inventor
Ulrich Rosentreter
Rolf Henning
Marcus Bauser
Thomas Kraemer
Andrea Vaupel
Walter Huebsch
Klaus Dembowsky
Olga Salcher-Schraufstaetter
Johannes-Peter Stasch
Thomas Krahn
Elisabeth Perzborn
Original Assignee
Bayer Ag
Ulrich Rosentreter
Rolf Henning
Marcus Bauser
Thomas Kraemer
Andrea Vaupel
Walter Huebsch
Klaus Dembowsky
Salcher Schraufstaetter Olga
Stasch Johannes Peter
Thomas Krahn
Elisabeth Perzborn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL00353969A priority Critical patent/PL353969A1/xx
Priority to UA2002043618A priority patent/UA73957C2/uk
Application filed by Bayer Ag, Ulrich Rosentreter, Rolf Henning, Marcus Bauser, Thomas Kraemer, Andrea Vaupel, Walter Huebsch, Klaus Dembowsky, Salcher Schraufstaetter Olga, Stasch Johannes Peter, Thomas Krahn, Elisabeth Perzborn filed Critical Bayer Ag
Priority to EEP200200175A priority patent/EE200200175A/xx
Priority to IL14854500A priority patent/IL148545A0/xx
Priority to CA002386147A priority patent/CA2386147A1/en
Priority to AU77780/00A priority patent/AU775159B2/en
Priority to US10/110,284 priority patent/US7135486B1/en
Priority to HU0202810A priority patent/HUP0202810A3/hu
Priority to EP00967705A priority patent/EP1240145A2/de
Priority to JP2001528156A priority patent/JP2003511371A/ja
Priority to BR0014679-0A priority patent/BR0014679A/pt
Priority to SK434-2002A priority patent/SK4342002A3/sk
Priority to MXPA02003271A priority patent/MXPA02003271A/es
Publication of WO2001025210A2 publication Critical patent/WO2001025210A2/de
Publication of WO2001025210A3 publication Critical patent/WO2001025210A3/de
Priority to NO20021449A priority patent/NO323848B1/no
Priority to BG106546A priority patent/BG106546A/bg
Priority to HR20020375A priority patent/HRP20020375A2/xx
Priority to HK03106649.9A priority patent/HK1054386A1/zh
Priority to US11/359,927 priority patent/US7504421B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Es werden Verbindungen der allgemeinen Formel (I) beschrieben, ein Verfahren zu ihrer Herstellung sowie ihre Verwendung als pharmakologisch wirksame Substanzen für ein breites medizinisches Indikationsspektrum. Des weiteren werden selektive Adenosin-Rezeptorliganden, vorzugsweise selektive Adenosin-A1-, Adenosin-A2a- und/oder Adenosin-A2b-Rezeptorliganden, zur Prophylaxe und/oder Behandlung von Erkrankungen bereitgestellt, insbesondere von kardiovaskulären Erkrankungen; Erkrankungen des Urogenitalbereichs; Erkrankungen der Atemwege; inflammatorischen und neuroinflammatorischen Erkrankungen; Diabetes, insbesondere Diabetes mellitus; neurodegenerativen Erkrankungen; Schmerzzuständen; Krebs; sowie Leberfibrose und Leberzirrhose.
PCT/EP2000/009153 1999-10-01 2000-09-19 Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosin-rezeptorliganden WO2001025210A2 (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BR0014679-0A BR0014679A (pt) 1999-10-01 2000-09-19 2-tio-3,5-diciano-4-aril-6-aminopiridinas substituìdas e sua aplicação
JP2001528156A JP2003511371A (ja) 1999-10-01 2000-09-19 置換された２−チオ−３，５−ジシアノ−４−アリール−６−アミノピリジン類およびそれらの使用
SK434-2002A SK4342002A3 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
UA2002043618A UA73957C2 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
CA002386147A CA2386147A1 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
AU77780/00A AU775159B2 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
US10/110,284 US7135486B1 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
HU0202810A HUP0202810A3 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands, process for their preparation and pharmaceutical compositions containing them
EP00967705A EP1240145A2 (de) 1999-10-01 2000-09-19 Substituierte 2-thio-3,5-dicyyano-4-aryl-6-aminopyridine und ihre verwendung als adenosin-rezeptorliganden
PL00353969A PL353969A1 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
IL14854500A IL148545A0 (en) 1999-10-01 2000-09-19 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
EEP200200175A EE200200175A (et) 1999-10-01 2000-09-19 Asendatud 2-tio-3,5-ditsüano-4-arüül-6-aminopüridiinid ja nende kasutamine
MXPA02003271A MXPA02003271A (es) 1999-10-01 2000-09-19 12-tio-3, 5-diciano-4-aril-6-aminopiridinas sustituidas y su uso.
NO20021449A NO323848B1 (no) 1999-10-01 2002-03-22 Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner, fremstilling av samme, farmasoytisk sammensetning innbefattende samme og anvendelse av samme for fremstilling av medikament
BG106546A BG106546A (bg) 1999-10-01 2002-03-22 Заместени 2-тио-3,5-дициано-4-арил-6-аминопиридини и тяхното приложение
HR20020375A HRP20020375A2 (en) 1999-10-01 2002-04-29 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof
HK03106649.9A HK1054386A1 (zh) 1999-10-01 2003-09-16 取代的2-硫代-3，5-二氰基-4-芳基-6-氨基吡啶及其應用
US11/359,927 US7504421B2 (en) 1999-10-01 2006-02-21 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19947154.1 1999-10-01
DE19947154A DE19947154A1 (de) 1999-10-01 1999-10-01 Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10110284 A-371-Of-International 2000-09-19
US11/359,927 Division US7504421B2 (en) 1999-10-01 2006-02-21 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use

Publications (2)

Publication Number Publication Date
WO2001025210A2 WO2001025210A2 (de) 2001-04-12
WO2001025210A3 true WO2001025210A3 (de) 2001-10-11

Family

ID=7924036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009153 WO2001025210A2 (de) 1999-10-01 2000-09-19 Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosin-rezeptorliganden

Country Status (26)

Country Link
US (2) US7135486B1 (de)
EP (1) EP1240145A2 (de)
JP (1) JP2003511371A (de)
KR (2) KR20070106051A (de)
CN (1) CN1407971A (de)
AU (1) AU775159B2 (de)
BG (1) BG106546A (de)
BR (1) BR0014679A (de)
CA (1) CA2386147A1 (de)
CU (1) CU20020064A7 (de)
CZ (1) CZ301202B6 (de)
DE (1) DE19947154A1 (de)
EE (1) EE200200175A (de)
HK (1) HK1054386A1 (de)
HR (1) HRP20020375A2 (de)
HU (1) HUP0202810A3 (de)
IL (1) IL148545A0 (de)
MA (1) MA25688A1 (de)
MX (1) MXPA02003271A (de)
NO (1) NO323848B1 (de)
PL (1) PL353969A1 (de)
RU (1) RU2267482C2 (de)
SK (1) SK4342002A3 (de)
UA (1) UA73957C2 (de)
WO (1) WO2001025210A2 (de)
ZA (1) ZA200201806B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) * 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) * 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) * 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
ES2314100T3 (es) 2001-05-03 2009-03-16 Monsanto Technology Llc Derivados de piruvato.
JP2005518331A (ja) * 2001-05-24 2005-06-23 エンダシア，インコーポレイテッド Ａ１アデノシン受容体に対するａ１アデノシン受容体リガンドの親和性を増大させる方法と製剤
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
WO2004048349A1 (en) 2002-11-22 2004-06-10 Smithkline Beecham Corporation Farnesoid x receptor agonists
ES2338060T3 (es) * 2003-12-22 2010-05-03 Basilea Pharmaceutica Ag Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer.
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
DE102004042607A1 (de) * 2004-09-03 2006-03-09 Bayer Healthcare Ag Substituierte Phenylaminothiazole und ihre Verwendung
US20080194681A1 (en) * 2004-12-09 2008-08-14 Kalypsys, Inc. Novel Inhibitors of Histone Deacetylase for the Treatment of Disease
US20090221649A1 (en) * 2005-03-24 2009-09-03 Bayer Healthcare Ag Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage
EP1741709A1 (de) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl substituierte Amide mit gesättigtem Linker, und deren Verwendung als Pharmaka
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP5201817B2 (ja) * 2005-10-28 2013-06-05 大塚製薬株式会社 医薬組成物
DE102006009813A1 (de) * 2006-03-01 2007-09-06 Bayer Healthcare Ag Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel
EP1894924A1 (de) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterozyklische FXR Bindungsverbindungen
DE102006042143A1 (de) * 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
DE102006046410A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten
DE102006044696A1 (de) 2006-09-22 2008-03-27 Bayer Healthcare Ag 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung
DE102006056739A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung
DE102006056740A1 (de) * 2006-12-01 2008-06-05 Bayer Healthcare Ag Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung
EP1939181A1 (de) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
DE102007035367A1 (de) * 2007-07-27 2009-01-29 Bayer Healthcare Ag Substituierte Aryloxazole und ihre Verwendung
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007061763A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
DE102007061764A1 (de) * 2007-12-20 2009-06-25 Bayer Healthcare Ag Anellierte Cyanopyridine und ihre Verwendung
DE102008008838A1 (de) * 2008-02-13 2009-08-20 Bayer Healthcare Ag Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung
DE102008013587A1 (de) 2008-03-11 2009-09-17 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung
ES2428818T3 (es) * 2008-05-29 2013-11-11 Bayer Intellectual Property Gmbh Dicianopiridinas sustituidas con 2-alcoxi y su uso
DE102008062566A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Aminosäureester-Prodrugs und ihre Verwendung
DE102008062567A1 (de) * 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
KR101146010B1 (ko) * 2009-09-10 2012-05-16 서울대학교산학협력단 ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물
JP5843778B2 (ja) 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
US9301952B2 (en) 2010-04-23 2016-04-05 Kineta, Inc. Diarylpyridine anti-viral compounds
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
AU2011303420B2 (en) 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US20150157633A1 (en) * 2012-05-11 2015-06-11 The Board Of Regents Of The University Of Texas System Wnt protein signalling inhibitors
CN102924372B (zh) * 2012-11-01 2015-03-25 中国药科大学 一种抗肿瘤2-氨基-3-氰基吡啶及其应用、制备方法
WO2014164844A1 (en) * 2013-03-11 2014-10-09 Virobay, Inc. Cathepsin inhibitors
CN103980193B (zh) * 2014-05-27 2016-05-04 北京理工大学 2,6-二氨基-3,5-二氰基吡啶化合物的一锅法合成
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
SG11201809559UA (en) * 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
WO2018153900A1 (de) 2017-02-22 2018-08-30 Bayer Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit sglt-2-hemmern
WO2018153898A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten
WO2018153899A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc)
WO2018153897A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit hcn-kanal-hemmern
CN109651358B (zh) * 2017-10-11 2023-04-07 上海迪诺医药科技有限公司 4-氨基吡啶衍生物、其药物组合物、制备方法及应用
CN109745317A (zh) * 2017-11-08 2019-05-14 俞为群 腺苷受体激动剂的应用及评价方法及治疗膀胱泌尿功能障碍的药物
TR202002071A2 (tr) * 2020-02-11 2021-08-23 Bahcesehir Ueniversitesi Bcl-2 i̇nhi̇bi̇törü olarak kullanilan yeni̇ küçük terapöti̇k bi̇leşi̇kleri̇n fi̇zi̇k odakli olarak keşfi̇

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227485A (en) * 1990-06-19 1993-07-13 Griffith University Pyrazolo[3,4-d]pyrimidines with adenosine-like binding affinities
WO1999021617A2 (en) * 1997-10-29 1999-05-06 Medco Research, Inc. Allosteric adenosine receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5227485A (en) * 1990-06-19 1993-07-13 Griffith University Pyrazolo[3,4-d]pyrimidines with adenosine-like binding affinities
WO1999021617A2 (en) * 1997-10-29 1999-05-06 Medco Research, Inc. Allosteric adenosine receptor modulators

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
CHEM. HETEROCYCL. COMPD., vol. 33, no. 7, 1997, pages 793 - 798 *
CHEM. HETEROCYCL. COMPD., vol. 34, no. 2, 1998, pages 188 - 194 *
CHEMICAL ABSTRACTS, vol. 126, no. 23, 1997, Columbus, Ohio, US; abstract no. 305519m, KRIVOKOLYKO S G; DYACHENKO V D: "Esters and nitriles of 3-phenylacrylic and 3-(2-furyl)acrylic acid in synthesis of 6-amino-3,5-dicyano-4-phenyl(or 2-furyl)pyridine-2(1H)-thiones and selenones." page 500; XP002155852 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155853 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155854 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155855 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155856 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155857 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155858 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155859 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155860 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155862 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155863 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155864 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155865 *
DATABASE XFIRE Beilstein Informationssysteme GmbH, Frankfurt, DE; XP002155866 *
DATABASE XFIRE Beilstein Informatiossysteme GmbH, Frankfurt, DE; XP002155861 *
JACOBSON K A ET AL: "Adenosine Receptors: Pharmacology, Structure-Activity Relationships and Therapeutic Potential", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, no. 3, 7 February 1992 (1992-02-07), pages 407 - 422, XP002038897, ISSN: 0022-2623 *
RUSS. J. ORG. CHEM., vol. 30, no. 4.2, 1994, pages 620 - 626 *
RUSS. J. ORG. CHEM., vol. 34, no. 4, 1998, pages 557 - 563 *
UKR. KHIM. ZH., vol. 62, no. 11-12, 1996, pages 61 - 66 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Also Published As

Publication number Publication date
ZA200201806B (en) 2003-05-28
BR0014679A (pt) 2002-07-02
CN1407971A (zh) 2003-04-02
HK1054386A1 (zh) 2003-11-28
MA25688A1 (fr) 2003-04-01
MXPA02003271A (es) 2002-11-04
AU7778000A (en) 2001-05-10
HRP20020375A2 (en) 2005-04-30
CZ301202B6 (cs) 2009-12-09
US7504421B2 (en) 2009-03-17
RU2002111569A (ru) 2004-01-20
AU775159B2 (en) 2004-07-22
BG106546A (bg) 2003-03-31
KR20020032634A (ko) 2002-05-03
NO323848B1 (no) 2007-07-09
CA2386147A1 (en) 2001-04-12
CU20020064A7 (es) 2008-07-24
SK4342002A3 (en) 2002-08-06
KR20070106051A (ko) 2007-10-31
CZ20021143A3 (cs) 2002-07-17
JP2003511371A (ja) 2003-03-25
KR100832934B1 (ko) 2008-05-27
US7135486B1 (en) 2006-11-14
IL148545A0 (en) 2002-09-12
UA73957C2 (en) 2005-10-17
NO20021449D0 (no) 2002-03-22
NO20021449L (no) 2002-05-07
US20060264432A1 (en) 2006-11-23
HUP0202810A3 (en) 2003-02-28
EE200200175A (et) 2003-04-15
PL353969A1 (en) 2003-12-15
RU2267482C2 (ru) 2006-01-10
EP1240145A2 (de) 2002-09-18
DE19947154A1 (de) 2001-10-04
WO2001025210A2 (de) 2001-04-12
HUP0202810A2 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
WO2001025210A3 (de) Substituierte 2-thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung als adenosin-rezeptorliganden
WO2002064083A3 (en) Synthesis of 3-amino-thalidomide and its enantiomers
WO2006011050A3 (en) Pyridine derivatives
IL174475A0 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo['2,3-c]pyridin-2-ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2003000241A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika; corticosteroiden und betamimetika zur behandlung von entzündlichen und/oder obstruktiven atemwegserkrankungen
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2003044021A3 (en) Substituted indolizine-like compounds and methods of use
GEP20115213B (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
SI2527315T1 (sl) Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
WO2007076092A3 (en) Nitrogen- containing bicyclic hetroaryl compounds for the treatment of raf protein kinase-mediated diseases
WO2002100858A8 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof
WO2004043954A3 (en) Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2001045678A3 (de) Arzneimittel, verfahren zu dessen herstellung und dessen verwendung
EP1398029A8 (de) 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
WO2003087049A3 (de) Arzneimittelkombinationen enthaltend heterocyclische verbindungen und ein neues anticholinergikum
WO2005063764A3 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
IL126137A0 (en) New benzofuranone derivatives and a method for producing them
WO2006019685A3 (en) Compounds and their preparation for the treatment of alzheimer's disease by inhibiting beta-amyloid peptide production
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2004073375A8 (en) Podophyllotoxin derivatives as antitumor agents
WO2007092436A3 (en) Compounds for treating inflammatory disorders, demyelinating disorders and cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000967705

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 148545

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00331/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 106546

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/003271

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 77780/00

Country of ref document: AU

Ref document number: 518067

Country of ref document: NZ

Ref document number: 2386147

Country of ref document: CA

Ref document number: 4342002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2002-1143

Country of ref document: CZ

Ref document number: 2002/00855

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020027004179

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 528156

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20020375A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 1020027004179

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2002 2002111569

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 008166803

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: PV2002-1143

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000967705

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 518067

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 518067

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 77780/00

Country of ref document: AU